Case Report: Amphotericin B and Mefloquine as a Salvage Treatment of Alveolar Echinococcosis

Am J Trop Med Hyg. 2023 Jan 30;108(3):581-583. doi: 10.4269/ajtmh.22-0465. Print 2023 Mar 1.

Abstract

Alveolar echinococcosis is an emerging zoonotic disease caused by the parasite Echinococcus multilocularis. Most patients are diagnosed at a late stage, when lifelong treatment with benzimidazoles is required to stop disease progression. However, for patients who do not tolerate benzimidazole therapy, there are no alternatives. Here, we present a patient with advanced alveolar echinococcosis who was successfully treated with amphotericin B deoxycholate and mefloquine as a rescue therapy after he developed albendazole intolerance.

Publication types

  • Case Reports

MeSH terms

  • Albendazole / therapeutic use
  • Amphotericin B / therapeutic use
  • Animals
  • Anthelmintics* / therapeutic use
  • Echinococcosis* / drug therapy
  • Echinococcus multilocularis*
  • Humans
  • Male
  • Mefloquine / therapeutic use
  • Salvage Therapy

Substances

  • Mefloquine
  • Amphotericin B
  • Albendazole
  • Anthelmintics

Supplementary concepts

  • Alveolar echinococcosis